(CHE) Chemed - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US16359R1032
Stock: Healthcare, Plumbing, Restoration
Total Rating 33
Risk 88
Buy Signal -0.91
| Risk 5d forecast | |
|---|---|
| Volatility | 26.8% |
| Relative Tail Risk | -15.2% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -1.14 |
| Alpha | -40.14 |
| Character TTM | |
|---|---|
| Beta | 0.271 |
| Beta Downside | 0.229 |
| Drawdowns 3y | |
|---|---|
| Max DD | 38.54% |
| CAGR/Max DD | -0.18 |
EPS (Earnings per Share)
Revenue
Description: CHE Chemed March 04, 2026
Chemed Corporation (CHE) operates in two distinct segments: healthcare and plumbing/drainage.
The VITAS segment provides hospice and palliative care, utilizing a team of medical professionals and support staff. This business model focuses on end-of-life care, a specialized area within healthcare services.
The Roto-Rooter segment offers plumbing, drain cleaning, and water restoration services to both residential and commercial clients. This segment operates through a combination of company-owned branches, independent contractors, and franchisees, a common structure in service industries.
For more detailed analysis, consider exploring ValueRays comprehensive reports.
Headlines to watch out for
- VITAS hospice admissions and average daily census drive revenue
- Roto-Rooter service demand impacts plumbing segment growth
- Healthcare regulatory changes pose significant compliance risks
- Labor costs for medical and service staff influence profitability
- Interest rate fluctuations affect debt servicing and expansion plans
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 265.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.20 > 0.02 and ΔFCF/TA -2.21 > 1.0 |
| NWC/Revenue: 0.61% < 20% (prev 4.49%; Δ -3.87% < -1%) |
| CFO/TA 0.24 > 3% & CFO 388.3m > Net Income 265.2m |
| Net Debt (80.2m) to EBITDA (423.9m): 0.19 < 3 |
| Current Ratio: 1.05 > 1.5 & < 3 |
| Outstanding Shares: last quarter (14.0m) vs 12m ago -6.66% < -2% |
| Gross Margin: 31.14% > 18% (prev 0.35%; Δ 3079 % > 0.5%) |
| Asset Turnover: 152.9% > 50% (prev 145.7%; Δ 7.22% > 0%) |
| Interest Coverage Ratio: 109.0 > 6 (EBITDA TTM 423.9m / Interest Expense TTM 3.29m) |
Altman Z'' 10.00
| A: 0.01 (Total Current Assets 302.6m - Total Current Liabilities 287.1m) / Total Assets 1.64b |
| B: 1.80 (Retained Earnings 2.96b / Total Assets 1.64b) |
| C: 0.22 (EBIT TTM 359.1m / Avg Total Assets 1.65b) |
| D: 4.53 (Book Value of Equity 3.00b / Total Liabilities 660.6m) |
| Altman-Z'' Score: 12.16 = AAA |
Beneish M -2.89
| DSRI: 1.03 (Receivables 182.6m/171.2m, Revenue 2.53b/2.43b) |
| GMI: 1.13 (GM 31.14% / 35.14%) |
| AQI: 1.08 (AQ_t 0.61 / AQ_t-1 0.57) |
| SGI: 1.04 (Revenue 2.53b / 2.43b) |
| TATA: -0.08 (NI 265.2m - CFO 388.3m) / TA 1.64b) |
| Beneish M-Score: -2.89 (Cap -4..+1) = A |
What is the price of CHE shares?
As of March 10, 2026, the stock is trading at USD 403.47 with a total of 277,315 shares traded.
Over the past week, the price has changed by -4.25%, over one month by -9.86%, over three months by -3.92% and over the past year by -32.06%.
Over the past week, the price has changed by -4.25%, over one month by -9.86%, over three months by -3.92% and over the past year by -32.06%.
Is CHE a buy, sell or hold?
Chemed has received a consensus analysts rating of 4.67.
Therefore, it is recommended to buy CHE.
- StrongBuy: 2
- Buy: 1
- Hold: 0
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the CHE price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 443 | 9.8% |
| Analysts Target Price | 443 | 9.8% |
CHE Fundamental Data Overview March 08, 2026
P/E Trailing = 22.2399
P/E Forward = 17.3913
P/S = 2.2746
P/B = 5.7536
P/EG = 1.74
Revenue TTM = 2.53b USD
EBIT TTM = 359.1m USD
EBITDA TTM = 423.9m USD
Long Term Debt = 143.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 51.9m USD (from shortTermDebt, last quarter)
Debt = 154.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 80.2m USD (from netDebt column, last quarter)
Enterprise Value = 5.83b USD (5.75b + Debt 154.8m - CCE 74.5m)
Interest Coverage Ratio = 109.0 (Ebit TTM 359.1m / Interest Expense TTM 3.29m)
EV/FCF = 17.93x (Enterprise Value 5.83b / FCF TTM 325.5m)
FCF Yield = 5.58% (FCF TTM 325.5m / Enterprise Value 5.83b)
FCF Margin = 12.86% (FCF TTM 325.5m / Revenue TTM 2.53b)
Net Margin = 10.48% (Net Income TTM 265.2m / Revenue TTM 2.53b)
Gross Margin = 31.14% ((Revenue TTM 2.53b - Cost of Revenue TTM 1.74b) / Revenue TTM)
Gross Margin QoQ = 32.22% (prev 28.91%)
Tobins Q-Ratio = 3.56 (Enterprise Value 5.83b / Total Assets 1.64b)
Interest Expense / Debt = 0.34% (Interest Expense 521.0k / Debt 154.8m)
Taxrate = 27.21% (28.7m / 105.4m)
NOPAT = 261.4m (EBIT 359.1m * (1 - 27.21%))
Current Ratio = 1.05 (Total Current Assets 302.6m / Total Current Liabilities 287.1m)
Debt / Equity = 0.16 (Debt 154.8m / totalStockholderEquity, last quarter 979.4m)
Debt / EBITDA = 0.19 (Net Debt 80.2m / EBITDA 423.9m)
Debt / FCF = 0.25 (Net Debt 80.2m / FCF TTM 325.5m)
Total Stockholder Equity = 1.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.03% (Net Income 265.2m / Total Assets 1.64b)
RoE = 23.92% (Net Income TTM 265.2m / Total Stockholder Equity 1.11b)
RoCE = 28.66% (EBIT 359.1m / Capital Employed (Equity 1.11b + L.T.Debt 143.8m))
RoIC = 23.57% (NOPAT 261.4m / Invested Capital 1.11b)
WACC = 6.74% (E(5.75b)/V(5.91b) * Re(6.91%) + D(154.8m)/V(5.91b) * Rd(0.34%) * (1-Tc(0.27)))
Discount Rate = 6.91% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -4.27%
[DCF] Terminal Value 84.05% ; FCFF base≈342.5m ; Y1≈377.6m ; Y5≈486.0m
[DCF] Fair Price = 810.9 (EV 11.20b - Net Debt 80.2m = Equity 11.12b / Shares 13.7m; r=6.74% [WACC]; 5y FCF grow 11.79% → 2.90% )
EPS Correlation: 41.38 | EPS CAGR: 8.12% | SUE: -1.01 | # QB: 0
Revenue Correlation: 96.05 | Revenue CAGR: 5.10% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=5.40 | Chg7d=-0.492 | Chg30d=-0.492 | Revisions Net=-2 | Analysts=4
EPS current Year (2026-12-31): EPS=24.01 | Chg7d=-1.400 | Chg30d=-1.400 | Revisions Net=-3 | Growth EPS=+11.4% | Growth Revenue=+5.5%
EPS next Year (2027-12-31): EPS=26.83 | Chg7d=-0.553 | Chg30d=-0.553 | Revisions Net=-1 | Growth EPS=+11.8% | Growth Revenue=+6.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.5% (Discount Rate 7.9% - Earnings Yield 4.5%)
[Growth] Growth Spread = +3.1% (Analyst 6.5% - Implied 3.5%)
P/E Forward = 17.3913
P/S = 2.2746
P/B = 5.7536
P/EG = 1.74
Revenue TTM = 2.53b USD
EBIT TTM = 359.1m USD
EBITDA TTM = 423.9m USD
Long Term Debt = 143.8m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 51.9m USD (from shortTermDebt, last quarter)
Debt = 154.8m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 80.2m USD (from netDebt column, last quarter)
Enterprise Value = 5.83b USD (5.75b + Debt 154.8m - CCE 74.5m)
Interest Coverage Ratio = 109.0 (Ebit TTM 359.1m / Interest Expense TTM 3.29m)
EV/FCF = 17.93x (Enterprise Value 5.83b / FCF TTM 325.5m)
FCF Yield = 5.58% (FCF TTM 325.5m / Enterprise Value 5.83b)
FCF Margin = 12.86% (FCF TTM 325.5m / Revenue TTM 2.53b)
Net Margin = 10.48% (Net Income TTM 265.2m / Revenue TTM 2.53b)
Gross Margin = 31.14% ((Revenue TTM 2.53b - Cost of Revenue TTM 1.74b) / Revenue TTM)
Gross Margin QoQ = 32.22% (prev 28.91%)
Tobins Q-Ratio = 3.56 (Enterprise Value 5.83b / Total Assets 1.64b)
Interest Expense / Debt = 0.34% (Interest Expense 521.0k / Debt 154.8m)
Taxrate = 27.21% (28.7m / 105.4m)
NOPAT = 261.4m (EBIT 359.1m * (1 - 27.21%))
Current Ratio = 1.05 (Total Current Assets 302.6m / Total Current Liabilities 287.1m)
Debt / Equity = 0.16 (Debt 154.8m / totalStockholderEquity, last quarter 979.4m)
Debt / EBITDA = 0.19 (Net Debt 80.2m / EBITDA 423.9m)
Debt / FCF = 0.25 (Net Debt 80.2m / FCF TTM 325.5m)
Total Stockholder Equity = 1.11b (last 4 quarters mean from totalStockholderEquity)
RoA = 16.03% (Net Income 265.2m / Total Assets 1.64b)
RoE = 23.92% (Net Income TTM 265.2m / Total Stockholder Equity 1.11b)
RoCE = 28.66% (EBIT 359.1m / Capital Employed (Equity 1.11b + L.T.Debt 143.8m))
RoIC = 23.57% (NOPAT 261.4m / Invested Capital 1.11b)
WACC = 6.74% (E(5.75b)/V(5.91b) * Re(6.91%) + D(154.8m)/V(5.91b) * Rd(0.34%) * (1-Tc(0.27)))
Discount Rate = 6.91% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -4.27%
[DCF] Terminal Value 84.05% ; FCFF base≈342.5m ; Y1≈377.6m ; Y5≈486.0m
[DCF] Fair Price = 810.9 (EV 11.20b - Net Debt 80.2m = Equity 11.12b / Shares 13.7m; r=6.74% [WACC]; 5y FCF grow 11.79% → 2.90% )
EPS Correlation: 41.38 | EPS CAGR: 8.12% | SUE: -1.01 | # QB: 0
Revenue Correlation: 96.05 | Revenue CAGR: 5.10% | SUE: -4.0 | # QB: 0
EPS next Quarter (2026-06-30): EPS=5.40 | Chg7d=-0.492 | Chg30d=-0.492 | Revisions Net=-2 | Analysts=4
EPS current Year (2026-12-31): EPS=24.01 | Chg7d=-1.400 | Chg30d=-1.400 | Revisions Net=-3 | Growth EPS=+11.4% | Growth Revenue=+5.5%
EPS next Year (2027-12-31): EPS=26.83 | Chg7d=-0.553 | Chg30d=-0.553 | Revisions Net=-1 | Growth EPS=+11.8% | Growth Revenue=+6.2%
[Analyst] Revisions Ratio: -1.00 (0 Up / 2 Down within 30d for Next Quarter)
[Growth] Implied Growth Rate = 3.5% (Discount Rate 7.9% - Earnings Yield 4.5%)
[Growth] Growth Spread = +3.1% (Analyst 6.5% - Implied 3.5%)